Prevalence of bronchoconstriction in patients with bronchiectasis assessed prior to treatment with a dry powder preparation of mannitol Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Gamma-scintigraphic evaluation of the delivered dose, lung deposition rate and distribution pattern of 99m Tc-labelled tiotropium via dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 475s Year: 2003
Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study Source: Eur Respir J 2011; 38: 1071-1080 Year: 2011
Comparison of total and fine drug particle mass generated from two dry powder inhalers (DPIs) by 4-year old children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Deposition, retention and translocation of ultrafine carbonaceous particles from central and peripheral lung regions in healthy subjects and in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 459s Year: 2006
Single-breath, real time measurement of lung deposition of tobacco smoke fine particles: the correlation between particle burden and regional particle deposition fraction Source: Annual Congress 2007 - The versatile aspects of nicotine addiction Year: 2007
Comparison of aerosol deposition pattern in healthy vs. asthmatic subjects Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012
Impact of fine particle concentration in asthma control Source: International Congress 2019 – Long-term evaluation and control of airway diseases Year: 2019
Effect of breath-actuated mechanism on the emitted particle characteristics and lung deposition of a fixed combination drug Source: International Congress 2017 – Inhalers and their use Year: 2017
Dose proportionality of in vitro fine particle dose for dry powder inhaler combination products Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002
Impact of water immersion on capillary lung volume (Vc) in healthy subjects Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 493s Year: 2001
Measuring peripheral lung dimensions with the deposition of aerosol nanoparticles Source: Virtual Congress 2021 – Management of chronic cough and obstructive diseases Year: 2021
Reduction of particles by using a particle separator in pig barn environment reduces inflammatory response in healthy volunteers Source: Annual Congress 2012 - Respiratory diseases at at work: epidemiology, inflammation and challenge studies Year: 2012
Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Are patients with cystic fibrosis of six years and older able to use dry powder inhalers? A study of the effect of device resistance on flows and volumes Source: Eur Respir J 2004; 24: Suppl. 48, 386s Year: 2004
Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Effect of lung volume on acoustic transmission in normal subjects Source: Eur Respir J 2006; 28: Suppl. 50, 420s Year: 2006